About ECM Therapeutics
ECM Therapeutics is a Healthcare company based in Warrendale (United States) founded in 2018. It operates as a diagnostic and therapeutic products from extracellular matrix are developed. ECM Therapeutics has raised $26.1 million across 1 funding round. ECM Therapeutics offers products and services including ECM Therapeutic Products and Extracellular Vesicles. Its focus areas include Life Sciences, Oncology, Drugs and Bone Cancer. Its legal entity is ECM THERAPEUTICS INC. Its competitors include SpringWorks Therapeutics, Augmenix, AmacaThera, Regentis Biomaterials and LifeSprout and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
ECM Therapeutics was founded in 2018 and is based in Warrendale, United States. Focus is placed on the development of diagnostic and therapeutic products sourced from extracellular matrix, a naturally occurring material. These products address diseases and injuries, including an ECM hydrogel named EsophaGel designed to halt and reverse esophageal cancer progression and precursor stages linked to gastric reflux. Operations center on biotechnology applications for medical treatments.
- Headquarters Warrendale, United States
- SectorsHealthcare
- Website ecmtherapeutics.com
- Social LinkedIn
- Legal Name Ecm Therapeutics Inc
- Total Equity Funding$26.1M (USD)
in 1 rounds
- Latest Funding Round$26.1M (USD), Series B
May 2018
Products & Services of ECM Therapeutics
ECM Therapeutics offers a comprehensive portfolio of products and services, including ECM Therapeutic Products and Extracellular Vesicles.
Products from extracellular matrix for tissue repair and inflammation reduction.
Signaling molecules in ECM for regenerative applications in medical treatments.
Funding Insights of ECM Therapeutics
ECM Therapeutics has successfully raised a total of $26.1M through 1 strategic funding round. The most recent funding activity was a Series B round of $26.1 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.1M
- Total Rounds 1
- Last Round Series B — $26.1M
- First Round $26.1M
(May 2018)
All 1 funding rounds of ECM Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $26.1M | Series B | – | – | – |
People of ECM Therapeutics
5 people are tracked at ECM Therapeutics (5 in leadership).
| Name | Role | Group |
|---|---|---|
Paul Fagan | Chief Executive Officer | Leadership |
Katie Collins | Co-Founder, VP Business Development | Leadership |
Tyler Okel | Director of Quality | Leadership |
Jenna Dziki | Vice President, Product Development | Leadership |
Greg Fariss | Director Of Manufacturing | Leadership |
Complete people profiles for ECM Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ECM Therapeutics
2 dated milestones of ECM Therapeutics, from founding to its latest funding, stage changes and deals.
- Founded ECM Therapeutics is founded.
- Funding First funding round of $26.1M.
Competitors of ECM Therapeutics
ECM Therapeutics has 8 listed competitors in our database, 7 of them funded. They include SpringWorks Therapeutics, Augmenix, AmacaThera, Regentis Biomaterials and LifeSprout, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| springworkstx.com | 2017 | New York, United States | $229.6M | 305 | Small molecule therapeutics are developed for cancer and rare diseases. | |
| augmenix.com | 2008 | Waltham, United States | $46.6M | 153 | Hydrogel spacers are provided for prostate cancer radiation therapy. | |
| amacathera.ca | 2015 | Toronto, Canada | $14.22M | – | Injectable hydrogel platform developed for therapeutic medical applications. | |
| regentis.co.il | 2004 | Or Akiva, Israel | $25M | – | Regentis Biomaterials is focused on tissue repair hydrogel technology. | |
| lifesproutbio.com | 2015 | Baltimore, United States | $44.7M | 12 | Synthetic soft tissue substitutes for cosmetics and reconstructive surgery | |
| qsambio.com | 2004 | Palm Beach, United States | – | 4 | Developer of nuclear medicines for the treatment of bone cancer treatment & bone marrow ablation | |
| vujade-life.com | 2017 | Hoboken, United States | $3.94M | – | Therapies for preventing cancer metastasis and recurrence are developed. | |
| biosyntech.com | 1994 | Laval, Canada | $1.4M | – | Biotherapeutic thermogels are developed for tissue repair applications. |
Detailed competitors of ECM Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ECM Therapeutics
The website of ECM Therapeutics (ecmtherapeutics.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 3.9% vs previous month
Websites whose visitors overlap most with ECM Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novasenta.com | 100% | 2.4K | #6,002,810 | View details | |
| plexision.com | 98% | 3.2K | #5,846,553 | View details | |
| bluespherebio.com | 98% | 2.5K | #6,529,430 | View details | |
| peptilogics.com | 96% | 2.1K | #8,263,579 | View details | |
pittbioforge.org | pittbioforge.org | 93% | – | #6,533,171 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for ECM Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as ECM Therapeutics (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ecm Therapeutics
Complete news archive for ECM Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ECM Therapeutics
ECM Therapeutics was founded in 2018.
ECM Therapeutics is headquartered in Warrendale, United States. It is registered at Warrendale, Pennsylvania, United States.
ECM Therapeutics is a funded company, having raised a total of $26.1M across 1 funding round to date. The company's 1st funding round was a Series B of $26.1M, raised on May 2018.
ECM Therapeutics was founded in 2018 and is based in Warrendale, United States. Focus is placed on the development of diagnostic and therapeutic products sourced from extracellular matrix, a naturally occurring material. These products address diseases and injuries, including an ECM hydrogel named EsophaGel designed to halt and reverse esophageal cancer progression and precursor stages linked to gastric reflux. Operations center on biotechnology applications for medical treatments.
ECM Therapeutics's top competitors include SpringWorks Therapeutics, AmacaThera and Augmenix.
ECM Therapeutics offers ECM Therapeutic Products and Extracellular Vesicles.
ECM Therapeutics operates through Ecm Therapeutics Inc.